Close Menu

Siemens

The company's recent license agreement with Abbott is part of its plan to move its Simoa technology into the clinic via partners in LDT and IVD development.

Semi-quantitative SARS-CoV-2 serology tests enable users to measure levels of neutralizing antibodies, but tests need to be more comparable across manufacturers, Siemens said.

The company is developing technology to analyze capillary blood samples from a finger prick using one-tenth the volume typically collected by traditional venipuncture.

An initial program aims at the development of a serum neurofilament light chain immunoassay to support Novartis' MS and other neuroscience programs.

News items for in vitro diagnostics industry for the week of Sept. 14, 2020.

Questions around performance and a lack of clear clinical utility have hampered uptake, though improved standardization and vaccine launches could boost usage.

The collaboration seeks to standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization.

The FDA does not allow labs to report hs-troponin results below assays' limits of quantitation, which some argue leaves actionable information on the table.

Quidel sued Siemens Healthineers claiming false advertising associated with a competing assay that measures thyroid-stimulating immunoglobins to detect Graves' disease.

A number of research groups and companies are exploring use of T-cell response testing in areas like vaccine development and assessing spread of the virus.

Pages